biosimilars congress · * exclusive exhibitor event | ** networking event note: conference schedule...

August 20-21, 2018 Tokyo, Japan

conferenceseries.com

http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific

Participation200+ 15+

InteractiveSessions

10+KeynoteLectures

50+PlenaryLectures

10+Exhibitors

B2BMeetings

3+Workshops

12th Asian Biologics and Biosimilars Congress

Invitation...Dear Colleagues,

Conference Series llc LTD extends its welcome to 12th Asian Biologics and Biosimilars Congress during August 20-21, 2018 at Tokyo, Japan with a theme “Biologics & Biosimilars: Power of the Past - Force of the Future”. Conference Series llc LTD through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community.

Conference Series llc LTD Organizes 1000+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board members.

The Asian Biosimilars Congress 2018 brings together biopharmaceutical. industry colleagues, scientists, researchers, regulatory, and clinical experts from around. the globe to bring to you the cutting edge information for the development of biologics and biosimilars and is designed to bring forth the most up to. date information for the development of biosimilars. World-renowned speakers, the. most recent research, advances, and the newest updates in Biologics and Biosimilars are hallmarks of this conference.

Join your peers from around the world for this wonderful opportunity to reach the. largest assembly of participants from the Biologics/Biosimilars community, meet with thought leadership experts, share your new research, and show off your cutting edge technology at this 3-day event.

Organizing Committee MembersAsif MahmoodDisease Area ClusterLead for BiosimilarsPfizer, USA

Mahmoud BalbaaProfessorAlexandria UniversityEgypt

Tucker HerbertSr. Director & HeadMedImmune, USA

Devrim SatikGlobal Regulatory Affairs AMESA ME Zone Head Sanofi, Turkey

Michel MikhailSenior VPInternational Expert in Biosimilars, USA

Suzette DiMascioCEO & PresidentCSI Specialty GroupUSA

Jianguo YangCEOTAYU Huaxia biotech medical group Beijing, China

Pankaj ChaudhariManager - Regulatory Affairs (Biosimilars)IQVIA, India

T. Santha RajuSr. Director & HeadMedImmune, USA

Divya Chadha ManekHead of CommercialBusiness NIHR, United KingdomPierre A MorgonCEO MRGN Advisors Certified CxO Vaccitech LimitedSwitzerland


* Exclusive Exhibitor Event | ** Networking EventNote: Conference schedule is subject to change.Note: Workshops and Symposia slots are available. To book slot for Workshop and Symposium send us the proposal.

Ten

tative

Age

nda

August 20, 2018 Monday

Time Session

08:30-09:30 Registrations

09:30-11:30 Keynote Forum

Group Photo

11:30-11:45 Network & Refreshments Break*

11:45-13:00Latest Biosimilars in Asian Scenario | Regulatory Approach for Biosimilars | Brexit Effect on BiosimilarsChallenges in Developing Biosimilars

13:00-13:45 Lunch Break**

13:45-16:00 Biosimilar Market and Cost Analysis | Pharmacovigilance of Biosimilars


16:15-18:00 Biosimilars Research Pipeline | Globalization of Biosimilars | Biosimilar Companies and Market Analysis

August 21, 2018 Tuesday

Time Session

08:30-09:30 Registrations

09:30-10:30 Keynote Forum

10:30-11:30 Emerging Trends in Biosimilars | Clinical Studies on Biosimilars


11:45-13:00 Emerging Biosimilars in Therapeutics | Biosimilars Analytical Strategies | Bioequivalence Assessment

13:00-13:45 Lunch Break**

13:45-16:00 Legal Issues and BPCI Act | Intellectual Property Rights | BCS & IVIVC Based Biowaivers


16:15-18:00 Poster Presentations

Award Ceremony


Day 1 August 20, 2018Kenote Forum

10:30-11:30Title: Biosimilars: A Biologic Revolution - Implications for SafetyAsif Mahmood, Pfizer, USA

Networking and Refreshment & Group Photo: 11:30-11:50

11:50-12:50Title:Biosimilars Interchangeability: TheDraft regulation in the USAMichel Mikhal, International Expert in Biosimilars, USA

Sessions: Latest Biosimilars in Asian Scenario | Challenges in Developing Biosimilars | Biosimilar Market and Cost Analysis | Clinical Studies on BiosimilarsSessions Chair: TBA

12:50-13:20Title: Decoding How Key Stakeholders Drive Biosimilar AdoptionTucker Herbert, Stanford University, USA

Lunch Break: 13:20-14:20

14:20-14:50Title: Institutional experiences in clinical evaluation of biosimilarsDivya Chadha Manek, NIHR Clinical Research Network, UK

14:50-15:20Title: Opportunities, Challenges and Strategies for Commercial Success in Global biosimilar MarketPankaj S Chaudhari, Ipca Laboratories, India

Networking and Refreshment & Group Photo: 15:20-15:40

15:40-16:10Title: Biosimilars in the United States: A progress report and a peek in to the futureKurt R Karst, Hyman Phelps & McNamara, USA

16:10-16:40Title: Bioassay-directed isolation of hypotensive alkaloids from Holarrhena pubescensK Aftab, Research Institute of Chemistry, University of Karachi, Pakistan

Panel Discussion

Day 2 August 21, 2018Kenote Forum

10:00-11:00Title: Theodor Bilharz Research Institute therapeutic products and health tools Ismaeil Saad, Theodor Bilharz Research Institute, Egypt

11:00-12:00Title: Expression of shiga-like toxin fused to vascular endothelial growth factor in E.coli for targeting angiogenesis Osama O Ibrahim, Bioinnovation, USA

Lunch Break: 12:00-13:00B2B Meeting

Awards & Closing CeremonyThis is tentative agenda for the scheduled event. Please note that the timings in this program may subject to change. For more de-tails please contact: [email protected]

Scie

ntifi

c Pro

gram


Con

feren

ce H

ighlig

hsts


Track 1: Latest Biosimilars in Asian ScenarioTrack 2: Regulatory Approach for BiosimilarsTrack 3: Challenges in Developing BiosimilarsTrack 4: Biosimilar Market and Cost AnalysisTrack 5: Pharmacovigilance of BiosimilarsTrack 6: Biosimilars Research PipelineTrack 7: Globalization of BiosimilarsTrack 8: Emerging Trends in BiosimilarsTrack 9: Clinical Studies on BiosimilarsTrack 10: Emerging Biosimilars in TherapeuticsTrack 11: Biosimilars Analytical StrategiesTrack 12: Legal Issues and BPCI ActTrack 13: Intellectual Property RightsTrack 14: Brexit Effect on BiosimilarsTrack 15: BCS & IVIVC Based BiowaiversTrack 16: Biosimilar Companies and Market AnalysisTrack 17: Bioequivalence AssessmentTrack 18: Entrepreneurs Investment Meet


Abdel Halim HarrathKing Saud UniversitySaudi Arabia

Alex BrillAmerican Enterprise Institute USA

Andy UpsallAntibody Analytics United Kingdom

Beat FluehmannVifor Pharma Switzerland

Christina VesselyBiologics Consulting, USA

Darius PanaliganMerck Biosimilars Switzerland

Fiona M GreerSGS Life Sciences United Kingdom

Gordon BolgerNucro-Technics Inc., Canada

James HarrisHealthcare Economics LLC USA

Kamali Chance Quintiles, IMSUSA

Lisa Mueller Women In BioUSA

Abe Hershkovitz Hershkovitz & Associates, PLLC USA

Alexander Pitters Kaiser Optical SystemsFrance

Angela FurlanettoDLA Piper (Canada) LLPCanada

Candida Fratazzi BBCR Consulting USA

Christoph VolpersMichalski & Hüttermann Germany

Denise Kettelberger Patterson Thuente Pedersen, P.A.,USA

Francesco MarchesiRegina Elena National Cancer Institute, Italy

Gregory Glover Principal at Pharmaceutical Law Group PCUSA

Jianguo Yang Abpro, USA

Kerisha Bowen Dentons US LLC USA

Luis UlloaRutgers University- New Jersey Medical School USA

Afshin Safavi BioAgilytix Labs USA

András Guttman University

Aparna Kasinath Syngene InternationalIndia

Charu Manaktala Quintiles IMSIndia

Chris LeintzPfizerUSA

Dipti GulatiPJI BiotechUSA

Frank Cheng Alban Pharma China

Gustavo H. Marin UNLP-CONICET Argentina

Yahua (Jenny) Chen, Wolf, Greenfield & Sacks P.CUSA

Krishna Menon CellceutixUSA

Marcus Mreyen Protagen Protein Services, GmbH Germany

Alan L. Epstein USC Keck School of MedicineUSA

Andreu Soldevila LeanBioProSpain

Asif Mahmood PfizerUSA

Past Speakers


Christelle Dagoneau Catalent Biologics USA

Daniel Galbraith BioOutsource Ltd United Kingdom

Divya Chadha Manek, NIHRUK

Gene Ransom CEO MedChi, The Maryland State Medical Society USA

Hossein Pakdaman, Iranian Neurological AssociationIran

Jill MyersFortress BiotechUSA

Laszlo Endrenyi University of TorontoCanada

Mariana Babayeva Touro College of PharmacyUSA

Mario DiPaola Blue Stream Laboratories, Inc, USA

Patrick Lucy Pfenex IncUSA

Robert Salcedo BioSciences Corp USA

Siddhartha Roy Bose InstituteIndia

Timothy Shea Sterne, Kessler, Goldstein & Fox P.L.L.C.,USA

Schellenberger Volker Schellenberger Amunix Operating Inc., USA

Mark Emalfarb Dyadic International, Inc., USA

Nigel Rulewski QuintilesUSA

Raj DavePillsbury Winthrop Shaw Pittman LLP USA

Ronald A Rader Biotechnology Information InstituteUSA

Subir RoyNovartisIndia

Tom CarverJ A Kemp - Patent and Trade Mark AttorneysUnited Kingdom

William Sarraille Sidley Austin LLP USA

Milind Antani Nishith Desai AssociatesIndia

Noelle Sunstrom NeuClone Pty Ltd, Australia

Raymond A Huml QuintilesIMSUSA

Ruediger Jankowsky, Cinfa Biotech GmbH, Germany

Samantha (Little) HowardCovance Clinical Research Unit, Inc., United Kingdom

UpendraNagaichAmity Institute of PharmacyIndia

Wolfgang RehmannTaylor Wessing Germany

Neil Schauer Schauer Biologics Consulting, LLC, USA

Min Zhang AstraZenecaUSA

Oxana Iliach Quintiles IMS Canada

Ricahrd Littlewood Appliedstrategic UK

Sarfaraz K. Niazi Adello Biologics LLCUSA

Sunit Maity Zumutor Biologics India

Vivek morya Centre for policy researchIndia

Zhaoyang LiSanofiUSA

Glimpses of Asian Biosimilars 2017


Tourist Attractions


Tokyo is Japan’s capital and the largest metropolitan area in the world. It is also one of Japan’s 47 prefectures, consisting of 23 central city wards and multiple cities, towns and villages west of the city center. The Izu and Ogasawara Islands are also part of Tokyo. Prior to 1868, Tokyo was known as Edo. A small castle town in the 16th century, Edo became Japan’s political center in 1603 when Tokugawa Ieyasu established his feudal government there. A few decades later, Edo had grown into one of the world’s most populous cities. With the Meiji Restoration of 1868, the emperor and capital moved from Kyoto to Edo, which was renamed Tokyo (“Eastern Capital”).

World’s highest Skywalk- the Tokyo Sky tree is the tallest free-standing tower in the world, measuring 634m. The observation deck at 450m is the world’s highest skywalk and offers panoramic views of the city.

Tokyo is a fascinating city, where the latest trends and the oldest traditions meet. From ancient cherry-blossomfestivals to the vibrant Harajuku neighbourhood, Tokyo offers a seemingly unlimited choice of shopping, entertainment, culture and dining to its visitors.

The city’s history can be appreciated in districts such as Asakusa, and in many excellent museums, historic temples and gardens. Contrary to common perception, Tokyo also offers a number of attractive green spaces in the city centre and within relatively short train rides at its outskirts.

You’ll fall in love with Japan

Venue:

Radisson Narita, Tokyo 650-35 Nanae, Tomisato-Shi

Narita 286-0221, Japan

Mail us to know more!For Abstract Submission Guidelines | For Reserving your slot | Proposals | Registration | Posters | Accommodations

No doubt you have lots of queries... Why not get in touch..!

Drop us your query with details and we will call you right away

Venue

For Queries Contact: Victorya Jones | Program Director

Email: [email protected] Ph: +1-650-889-4686 Ext: 6093

For Exhibition & Sponsorship Contact: Victorya Jones

Email: [email protected]

Hosted by Conference Series llc LTD47 Churchfield Road, London, W3 6AY

Toll Free: [email protected]


biosimilars congress · * exclusive exhibitor event | ** networking event note: conference schedule...

Documents